ArticleOncogene1999
Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 70 citations in OpenAlex.
- Facilitatory effect of insulin treatment on hepatocellular carcinoma development in diabetes.BMC research notes · 2017Article
- Cell cycle proteins as promising targets in cancer therapy.Nature reviews. Cancer · 2017Review
- Protein tyrosine phosphatases as potential therapeutic targets.Acta pharmacologica Sinica · 2014Review
- Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter.Oncogene · 2013Article
- LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation.Acta pharmacologica Sinica · 2009Article
- Mammary involution and breast cancer risk: transgenic models and clinical studies.Journal of mammary gland biology and neoplasia · 2009Review
- In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.Anti-cancer agents in medicinal chemistry · 2008Review
- Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.Journal of mammary gland biology and neoplasia · 2008Review
- Targeting PTPs with small molecule inhibitors in cancer treatment.Cancer metastasis reviews · 2008Review
- Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2008Article
- Expression of CDC25 phosphatases in human gastric cancer.Digestive diseases and sciences · 2008Article
- The role and target potential of protein tyrosine phosphatases in cancer.Current oncology reports · 2008Review
- Variations in intracellular levels of TATA binding protein can affect specific genes by different mechanisms.Molecular and cellular biology · 2008Article
- Hint1 is a haplo-insufficient tumor suppressor in mice.Oncogene · 2006Article
- Regulating mammalian checkpoints through Cdc25 inactivation.EMBO reports · 2003Review
- Increased susceptibility to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in transgenic mice overexpressing c-myc and epidermal growth factor in alveolar type II cells.Journal of cancer research and clinical oncology · 2003Article
- Pre-clinical applications of transgenic mouse mammary cancer models.Transgenic research · 2002Review
- Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma.The Journal of cell biology · 2002Article
- Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.British journal of cancer · 2001Article
- Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase.Molecular and cellular biology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Cdc25 phosphatases activate cyclin-dependent kinases (Cdks) by dephosphorylating critical phospho-tyrosine and phospho-threonine residues on these proteins. Several types of studies indicate that Cdc25s can enhance cell proliferation and oncogenesis. Furthermore, overexpression of Cdc25A and/or B have been detected in several types of primary human cancers, including breast cancers. To further assess the oncogenic capacity of Cdc25B in vivo, we have generated transgenic mice that overexpress Cdc25B in the mammary epithelium, driven by the MMTV - LTR promoter. Although these mice are grossly normal for up to 18 months, the ectopic expression of Cdc25B in their mammary glands increases the susceptibility of these mice to induction of mammary tumors by the carcinogen 9,10-dimethyl-1, 2-benzanthracene (DMBA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.